NCT00744978 - Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Alzheimer's Disease

Interventions

DRUG

Varenicline

0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks

DRUG

Placebo

Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.

Trial Locations (8)

Pfizer Investigational Site, Seongnam

Pfizer Investigational Site, Busan

Pfizer Investigational Site, Daegu

Pfizer Investigational Site, Incheon

Pfizer Investigational Site, Seoul

Pfizer Investigational Site, Seoul

Pfizer Investigational Site, Seoul

Pfizer Investigational Site, Suwon